PTLA Overview
Upcoming Projects (PTLA)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (PTLA)
-
Don’t see a project related to the company you care about? Create your own!
Expired Projects (PTLA)
-
After a surprise early approval for Betrixaban what is its potential in the market?
Ticker: PTLA
Execute By: Jul 12, 2017
Upcoming & Overdue Catalysts (PTLA)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (PTLA)
-
Portola (PTLA) Expects FDA Decision on Andexxa (Andexanet Alfa) on May 4, 2018
Ticker: PTLA
Occurred on: May 03, 2018 -
FDA Decision on Supplemental Application for Portola's (PTLA) Andexxa (Andexanet Alfa) Expected in May 4 2018
Ticker: PTLA
Occurred on: May 03, 2018 -
Portola (PTLA) Expects European Medicines Agency Decision on Betrixaban in Q1 2018
Ticker: PTLA
Occurred on: Mar 23, 2018 -
Portola to present abstracts for Andexanet Alfa at ACC.18
Ticker: PTLA
Occurred on: Mar 12, 2018 -
Portola (PTLA) Expects EMA Decision on Andexxa (Andexanet Alfa) in Q1 2018
Ticker: PTLA
Occurred on: Feb 20, 2018 -
EMA Decision on Supplemental Application for Portola's (PTLA) Andexxa (Andexanet Alfa) Expected in First Half of 2018
Ticker: PTLA
Occurred on: Feb 20, 2018 -
Portola (PTLA) Expects CHMP Opinion in Q1 2018 for Andexxa (Andexanet Alfa) in Treatment of Serious Uncontrolled Bleeding Events
Ticker: PTLA
Occurred on: Feb 20, 2018 -
Portola (PTLA) Expects US Launch in August 2017 for Betrixaban in Prevention of VTE in Acute Medically Ill Patients
Ticker: PTLA
Occurred on: Sep 05, 2017 -
Portola (PTLA) Expects BLA Re-Submission in Q2 for Andexxa (Anadexanet Alfa)
Ticker: PTLA
Occurred on: Aug 03, 2017 -
PDUFA Date of June 24th for Portola's (PTLA) Betrixaban in the Prevention of VTE in Acute Medically Ill Patients
Ticker: PTLA
Occurred on: Jun 23, 2017 -
Portola (PTLA) FDA Advisory Committee Meeting in Q2 2017 for Betrixaban in the Prevention of VTE in Acute Medically Ill Patients
Ticker: PTLA
Occurred on: Feb 08, 2017 -
PDUFA date of August 17 2016 under priority review for the BLA filling of Andexanet alfa, a Factor Xa ihibitor reversal agent
Ticker: PTLA
Occurred on: Aug 17, 2016 -
Phase 3 data of Betrixaban (The APEX Study) for the prevention of Venous thromboembolism (VTE) by late 1Q 2016
Ticker: PTLA
Occurred on: Mar 24, 2016 -
Boehringer Ingelheim's Praxbind Approved by FDA for Use As an Emergency Reversing Agent in Patients Taking Pradaxa
Tickers: BOEHRINGER INGELHEIM, PTLA, BXLT, PFE, BMY
Occurred on: Oct 16, 2015
Strategic Initiatives (PTLA)
-
Dermavant Sciences Licenses Portola's (PTLA) Cerdulatinib for Topical Non-Cancer Applications
Tickers: PTLA, Dermavant Sciences
Announcement Date: Dec 21, 2016 -
Bristol-Myers Squibb and Pfizer Sign Collaboration with Portola Pharmaceuticals to Develop and Commercialize Investigational Andexanet Alfa in Japan
Tickers: BMY, PFE, PTLA
Announcement Date: Feb 02, 2016
